Wed, Aug 20, 2014, 6:57 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

  • redhot47fla redhot47fla Apr 9, 2013 1:08 PM Flag

    SGN-LIV1A for breast cancer: Is this new news? (It sounds new to me.)

    From today's press release: In addition, preclinical data demonstrate activity of a new ADC for metastatic breast cancer, SGN-LIV1A, utilizing the same proprietary ADC technology as ADCETRIS® (brentuximab vedotin)....

    SGN-LIV1A is an ADC that targets LIV-1, which is expressed in most subtypes of metastatic breast cancer. Preclinical data demonstrated that up to 92 percent of breast tumors analyzed expressed LIV-1, while expression was limited in normal tissue. SGN-LIV1A is comprised of an anti-LIV-1 monoclonal antibody linked to a synthetic cell-killing agent called monomethyl auristatin E (MMAE). SGN-LIV1A demonstrated significant antitumor activity in multiple preclinical models at well-tolerated doses. Seattle Genetics plans to submit an IND and initiate a phase 1clinical trial of SGN-LIV1A for breast cancer in 2013. (Abstract 3962)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
42.99-0.27(-0.62%)Aug 20 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.